Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus FOLFIRI safety and quality-of-life study in previously oxaliplatin-treated metastatic colorectal cancer
NL-OMON37124Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in metastatic colorectal adenocarcinoma (mCRC), sponsored by Sanofi. Primary endpoints: Number of patients reporting adverse events and Number of patients reporting laboratory abnormalities. Started Nov 2012; status: active, not recruiting.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON37124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37124.